Controlling tumor growth and progression using light-based techniques
Optogenetic Control of Tumor Initiation and Tumor Progression in vivo
['FUNDING_OTHER'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-10817202
This study is exploring a new way to control how tumors grow in mice using light, which helps scientists learn more about how lung cancer develops and could lead to better treatments for people with cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-10817202 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new method to control the initiation and progression of tumors in mouse models using optogenetics, which involves light-regulated proteins. By precisely controlling when and where tumors form, researchers aim to better understand the signaling pathways that drive cancer development, particularly in lung cancer. The approach allows for real-time manipulation of oncogenic proteins and gene expression, providing insights into tumor behavior and the tumor microenvironment. This innovative technique could lead to more effective cancer therapies by enabling targeted interventions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with lung cancer or those at high risk for developing lung cancer.
Not a fit: Patients with cancers unrelated to the lung or those who are not eligible for experimental treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to breakthroughs in cancer treatment by allowing for precise control over tumor growth and progression.
How similar studies have performed: Other research has shown promise with optogenetic approaches in various biological systems, suggesting potential for success in this novel application for cancer.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KARGINOV, ANDREI V — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: KARGINOV, ANDREI V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer, Cancer Causing Agents